Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as panitumumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as
irinotecan, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. Giving panitumumab together with irinotecan may kill
more tumor cells.
PURPOSE: This phase II clinical trial is studying giving panitumumab together with irinotecan
to see how well it works as third-line therapy in treating patients with metastatic
colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
GERCOR - Multidisciplinary Oncology Cooperative Group Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)